US Capitol Capsule: NIH I-Corps takes startups on focused path to commercialization

Before Southern California biotech startup BCN Biosciences became engaged with a new program at the National Institutes of Health (NIH), the firm thought it had one indication for its experimental small molecule BCN057 (YEL002) – radiation mitigation.

Before Southern California biotech startup BCN Biosciences became engaged with a new program at the National Institutes of Health (NIH), the firm thought it had one indication for its experimental small molecule BCN057 (YEL002) – radiation mitigation.

The company also thought it was targeting the appropriate customers – radiation and medical oncologists – and would need at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category